Abbott Laboratories fell after disappointing Q4 results and guidance, driven by challenges in its nutrition business segment.
Abbott Laboratories (NYSE:ABT) closed at $87.77 on May 22, 2026, reflecting a 5.81% decline over the past month and a 33.43% drop over the last 52 weeks. The company’s market capitalization stands at $152.88 billion.
The decline followed Q4 results and forward guidance that fell short of expectations, primarily due to headwinds in its nutrition business. Hedge fund holdings in Abbott increased to 71 in Q4 2025 from 68 in the prior quarter, though the stock was not among the most popular picks for 2026.
Analysts noted that while Abbott remains a diversified healthcare player, some AI-focused stocks may offer stronger upside potential with lower downside risk.